Biomarkers for Allogeneic HCT Outcomes

Biomarkers for Allogeneic HCT Outcomes

Allogeneic hematopoietic cell transplantation (HCT) remains the only curative therapy for many hematological malignant and non-malignant disorders. However, key obstacles to the success of HCT include graft-versus-host disease (GVHD) and disease relapse due to absence of graft-versus-tumor (GVT) eff...

Full description

Bibliographic Details
Main Authors: Djamilatou Adom, Courtney Rowan, Titilayo Adeniyan, Jinfeng Yang, Sophie Paczesny
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Immunology
Subjects:
biomarkers
graft-versus-host disease
graft-versus-tumor
hematopoietic cell transplantation
proteomics
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.00673/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.00673/full

Similar Items